Noile-Immune Biotech Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	5	7	316	625	100
Revenue Growth (YoY)	-28.57%	-97.78%	-49.44%	525.00%	3.09%
Cost of Revenue	-	68	42	7	22
Gross Profit	5	-61	274	618	78
Selling, General & Admin	442	429	404	390	330
Research & Development	360	579	646	334	514
Operating Expenses	802	1,008	1,050	724	844
Operating Income	-797	-1,069	-776	-106	-766
Interest & Investment Income	6	-	-	-	-
Currency Exchange Gain (Loss)	-	-	-	5	-
Other Non Operating Income (Expenses)	-	107	-352	-283	-27
EBT Excluding Unusual Items	-791	-962	-1,128	-384	-793
Pretax Income	-791	-962	-1,128	-384	-793
Income Tax Expense	2	2	2	2	2
Net Income	-793	-964	-1,130	-386	-795
Net Income to Common	-793	-964	-1,130	-386	-795
Shares Outstanding (Basic)	43	43	41	39	38
Shares Outstanding (Diluted)	43	43	41	39	38
Shares Change (YoY)	0.01%	4.41%	5.87%	2.23%	7.89%
EPS (Basic)	-18.31	-22.26	-27.25	-9.85	-20.75
EPS (Diluted)	-18.31	-22.26	-27.25	-9.85	-20.75
Gross Margin	100.00%	-	86.71%	98.88%	78.00%
Operating Margin	-15940.00%	-15271.43%	-245.57%	-16.96%	-766.00%
Profit Margin	-15860.00%	-13771.43%	-357.60%	-61.76%	-795.00%
EBIT	-797	-1,069	-776	-106	-766
EBIT Margin	-	-	-245.57%	-16.96%	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.